Last updated on February 2020

Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children Known or Suspected to be Caused by Susceptible Gram-positive Organisms Including MRSA

Brief description of study

To determine the safety and descriptive efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections in children, aged birth to 17 years (inclusive), known or suspected to be caused by susceptible Gram-positive organisms, including methicillin-resistant strains of Staphylococcus aureus.

Clinical Study Identifier: NCT02814916

Find a site near you

Start Over

Southbay Pharma Research

La Palma, CA United States
  Connect »

Revival Research

Doral, FL United States
  Connect »

Global Research Holdings, LLC

Panama City, FL United States
  Connect »

University of Chicago

Chicago, IL United States
  Connect »

Children's Mercy Kansas City

Kansas City, KS United States
  Connect »

Cleveland Clinic

Cleveland, OH United States
  Connect »

The Clinical Trial Center

Jenkintown, PA United States
  Connect »

Hospital Sant Joan de D u

Esplugues de Llobregat, Spain
  Connect »

Hospital Universitario Donostia

Donostia-San Sebastian, Spain
  Connect »

PE PMC Acinus

Kropyvnytskyi, Ukraine
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.